Tibet Weixinkang Medicine Co., Ltd. (SHA:603676)

Market Cap	4.24B +4.2%
Revenue (ttm)	1.16B -9.1%
Net Income	216.65M -8.1%
EPS	0.50 -8.7%
Shares Out	432.33M
PE Ratio	19.56
Forward PE	n/a
Dividend	0.33 (3.29%)
Ex-Dividend Date	Nov 26, 2025

Volume	1,396,900
Average Volume	2,173,883
Open	9.95
Previous Close	9.94
Day's Range	9.75 - 9.95
52-Week Range	9.62 - 14.94
Beta	0.01
RSI	36.36
Earnings Date	Apr 24, 2026

About Tibet Weixinkang Medicine

Tibet Weixinkang Medicine Co., Ltd. engages in the research and development, production, and sale of chemical drugs and their bulk drugs in China. The company offers parenteral nutrition vitamins; electrolyte supplements; intravenous iron, trace, electrolytes, and amino acids supplements; antibiotics; acetylcysteine solution for inhalation; medicine for liver diseases; and other special fields. It also offers injection multivitamins, potassium magnesium aspartate for injection, iron sucrose injection, potassium aspartate injection, etc. The com...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2002
• Employees: 689
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 603676

Financial Performance

In 2025, Tibet Weixinkang Medicine's revenue was 1.14 billion, a decrease of -12.65% compared to the previous year's 1.30 billion. Earnings were 232.85 million, a decrease of -5.41%.